

Sarah Brand

List of Publications by Citations

Source: <https://exaly.com/author-pdf/8673005/sarah-brand-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

7

papers

87

citations

4

h-index

9

g-index

11

ext. papers

123

ext. citations

3.2

avg, IF

1.82

L-index

#	Paper	IF	Citations
7	Cost-effectiveness and public health benefit of secondary cardiovascular disease prevention from improved adherence using a polypill in the UK. <i>BMJ Open</i> , 2015 , 5, e007111	3	54
6	Efficacy and cost-effectiveness of dabigatran etexilate versus warfarin in atrial fibrillation in different age subgroups. <i>American Journal of Cardiology</i> , 2014 , 114, 849-55	3	15
5	Cost-effectiveness of empagliflozin in the UK in an EMPA-REG OUTCOME subgroup with type 2 diabetes and heart failure. <i>ESC Heart Failure</i> , 2020 , 7, 3910	3.7	5
4	Cost-effectiveness analysis of empagliflozin versus sitagliptin as second-line therapy for treatment in patients with type 2 diabetes in the United States. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 791-799	6.7	5
3	AbobotulinumtoxinA in the management of cervical dystonia in the United Kingdom: a budget impact analysis. <i>ClinicoEconomics and Outcomes Research</i> , 2015 , 7, 441-9	1.7	4
2	Economic evaluation of betibeglogene autotemcel (Beti-cel) gene addition therapy in transfusion-dependent β -thalassemia. <i>Journal of Market Access & Health Policy</i> , 2021 , 9, 1922028	3.7	4
1	1158-P: Cost-Effectiveness of Empagliflozin vs. Liraglutide as Second-Line Therapy for Type 2 Diabetes in the United States. <i>Diabetes</i> , 2020 , 69, 1158-P	0.9	